Literature DB >> 16759857

Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.

Kande K D Amarasinghe1, Artem G Evdokimov, Artem G Evidokimov, Kevin Xu, Cynthia M Clark, Matthew B Maier, Anil Srivastava, Anny-Odile Colson, Gina S Gerwe, George E Stake, Brian W Howard, Matthew E Pokross, Jeffrey L Gray, Kevin G Peters.   

Abstract

The sulfamic acid phosphotyrosine mimetic was coupled with a previously known malonate template to obtain highly selective and potent inhibitors of HPTPbeta. Potentially hydrolyzable malonate ester functionalities were replaced with 1,2,4-oxadiazoles without a significant effect on HPTPbeta potency.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16759857     DOI： 10.1016/j.bmcl.2006.05.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  9 in total

1.  Vascular Endothelial Receptor Tyrosine Phosphatase: Identification of Novel Substrates Related to Junctions and a Ternary Complex with EPHB4 and TIE2.

Authors:  Hannes C A Drexler; Matthias Vockel; Christian Polaschegg; Maike Frye; Kevin Peters; Dietmar Vestweber
Journal:  Mol Cell Proteomics       Date:  2019-08-19       Impact factor: 5.911

2.  The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration.

Authors:  Guanqiao Li; Ulka Sachdev; Kevin Peters; Xiaoyan Liang; Michael T Lotze
Journal:  J Immunother       Date:  2019-09       Impact factor: 4.456

Review 3.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

4.  Synthesis and crystal structure of new heterocyles derived from saccharin and uracil carrying 1,2,4-oxadiazolylmethyl group.

Authors:  Yaşar Dürüst; Besra Özer; Benson M Kariuki; Benson M Cariuki
Journal:  Mol Divers       Date:  2015-03-10       Impact factor: 2.943

5.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Authors:  Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Synthesis and crystal structure of new heterocycles containing 1,2,4-oxadiazole, 1,2,4-oxadiazolone (thione), hydantoin, and mercaptobenzimidazole units.

Authors:  Yaşar Dürüst; Özge Gözlükaya; Gülsün Özer; Frank R Fronczek
Journal:  Mol Divers       Date:  2014-05-04       Impact factor: 2.943

7.  Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.

Authors:  Shom Goel; Nisha Gupta; Brian P Walcott; Matija Snuderl; Cristina T Kesler; Nathaniel D Kirkpatrick; Takahiro Heishi; Yuhui Huang; John D Martin; Eleanor Ager; Rekha Samuel; Shuhan Wang; John Yazbek; Benjamin J Vakoc; Randall T Peterson; Timothy P Padera; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2013-07-30       Impact factor: 13.506

8.  Hydroxyindole carboxylic acid-based inhibitors for receptor-type protein tyrosine protein phosphatase beta.

Authors:  Li-Fan Zeng; Ruo-Yu Zhang; Yunpeng Bai; Li Wu; Andrea M Gunawan; Zhong-Yin Zhang
Journal:  Antioxid Redox Signal       Date:  2014-02-04       Impact factor: 8.401

Review 9.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.